Hologic's "3D Technology: A More Accurate Mammogram" Mobile Coach Tour Makes Special Stop at National Consortium of Breast

 Hologic's "3D Technology: A More Accurate Mammogram" Mobile Coach Tour Makes
 Special Stop at National Consortium of Breast Center's Annual Conference in
                                  Las Vegas

Company to highlight groundbreaking 3D technology and other innovations at
international breast health conference

PR Newswire

BEDFORD, Mass., March 21, 2013

BEDFORD, Mass., March 21, 2013 /PRNewswire/ --Hologic, Inc. (Hologic or the
Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of
premium diagnostics products, medical imaging systems and surgical products
dedicated to serving the healthcare needs of women, will bring its, "3D
Technology: A More Accurate Mammogram " mobile coach tour to the National
Consortium of Breast Center's (NCBC) 23^rd Annual National Interdisciplinary
Breast Center Conference in Las Vegas, Nevada March 23–27, 2013.

To view multimedia content on the Hologic 3D Mobile Coach Tour, please click:
http://www.multivu.com/players/English/60535-hologic-3d-mammography-mobile-tomo-tour/


"The "A More Accurate Mammogram" tour allows us to show another way Hologic 3D
mammography systems can be used to provide a great benefit to all women," said
Peter Soltani, Senior Vice President and General Manager, Women's Health. "A
mobile configuration can significantly expand the reach of this critical
screening tool, making it available to women who may not otherwise have access
to leading-edge breast imaging services. Clinical studies have shown that
Hologic's 3D mammography, combined with conventional 2D imaging, significantly
increases the detection of cancer and decreases the need for callbacks.[i]
Both of these advances are beneficial for all women, but may be of vital
importance to women with limited or difficult access to annual screening
mammography."

"The mortality rate from breast cancer in the United States has decreased by
31% since 1990, principally due to the contribution of mammographic screening
and improved therapies," said Gary Levine, M.D., Director of Breast Imaging,
Hoag Memorial Presbyterian Hospital and a leading authority on 3D mammography.
"Despite this, less than 60% of women in the U.S.undergo
regularscreening.Onereason given is the lack of easy access.Mobile
mammographyaddresses this by bringing high quality mammographic screening
directly to women, whether in a remote rural setting, retirement villageor
simply to provide conveniencein a corporate environment. The 3D mammography
coach on display at the NCBC conference provides a unique opportunity for
breast care professionals from all disciplines - radiology, surgery, oncology,
nursing, and social work - to see first-hand a new method for bringing the
latest mammographic technology - breasttomosynthesis - directly to women."

Hologic is sponsoring a breakfast symposium on the clinical benefits of 3D
mammography on Monday, March 25th. The guest speaker, Dr. Stephen Rose, is the
President and Founder of Rose Imaging Specialists in Houston, Texas and has
used 3D mammography extensively in his practice.

Other Hologic Women's Imaging Innovations Featured at NCBC

Other products displayed at this conference will showcase the versatility of
Hologic's women's imaging offerings including an Advanced Body Composition
Assessment package for the Company's osteoporosis assessment system, and a new
tomosynthesis biopsy option for use on the Affirm biopsy guidance system. The
tomosynthesis biopsy option is designed to allow radiologists to accurately
locate regions of interest for biopsy, even areas visible only on 3D images.
Using the tomosynthesis biopsy option, fewer exposures are required to
complete a biopsy, compared to a stereotactic procedure, resulting in an
overall reduction in radiation dose.

Hologic's synthesized 2D (C-View) images will also be shown. C-View images are
designed to be used in conjunction with 3D images to provide workflow
efficiencies and offer a lower dose alternative for patients. Hologic's C-View
synthesized 2D image option received CE marking in 2011 and while not yet
approved in the U.S., received a favorable vote from an FDA Advisory Panel in
October 2012.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium
diagnostics products, medical imaging systems and surgical products. The
Company operates four core business units focused on diagnostics, breast
health, GYN surgical and skeletal health. With a comprehensive suite of
technologies and a robust research and development program, Hologic is
committed to improving lives. The Company is headquartered in Massachusetts.
For more information, visit www.hologic.com.

Hologic, Affirm, and C-View are trademarks and/or registered trademarks of
Hologic, Inc., and/or its subsidiaries in the United States and/or other
countries.

Forward Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks
and uncertainties, including statements about the use of Hologic products.
There can be no assurance these products will achieve the benefits described
herein and that such benefits will be replicated in any particular manner with
respect to an individual patient as the actual effect of the use of the
products can only be determined on a case-by-case basis depending on the
particular circumstances and patient in question. Hologic expressly disclaims
any obligation or undertaking to release publicly any updates or revisions to
the data or statements presented herein to reflect any change in the Company's
expectations or any change in events, conditions or circumstances on which any
such data or statements are based.

Contacts:

Pat Hall

Director of Corporate
Communications                      Marianne McMorrow
                                    Global Marketing and Advertising Publicist
pat.hall@hologic.com                marianne.mcmorrow@hologic.com

781.999.7463 (Boston)               781.999.7723

919.245.3460 (North Carolina)

919.622.1341 (mobile)

[i] Skaane P, Bandos A, Gullien R, Eben E, Ekseth U, Haakenaasen U, Izadi M,
Jebsen I, Jahr G, Krager M, Niklason L, Hofvind S, Gur D. Comparison of
Digital Mammography Alone and Digital Mammography Plus Tomosynthesis in a
Population-based Screening Program Radioliogy. 2013 Jan 7.

SOURCE Hologic, Inc.

Website: http://www.hologic.com
 
Press spacebar to pause and continue. Press esc to stop.